CCO Annual Update
Prostate Cancer 2005
Epidemiology, Screening, and Biomarkers for Prostate Cancer |
Module 1 of 7 |
|
CME Program Director: E. David Crawford, MD
 
- Bob Djavan, MD, PhD
- Paul H. Lange, MD, FACS
|
|
|
Topics covered include:
- Introduction
- Effect of Screening
- Regional Variation
- Genetic Factors
- Environmental Factors
Learning Objectives
Upon completion of this activity, participants should be able to:
Review the epidemiology of prostate cancer. Describe novel markers for prostate cancer. Discuss the use of novel predictive markers of prostate cancer risk. Identify ways of optimizing PSA screening and defining biochemical failure.
|
Treatment of Localized Prostate Cancer |
Module 2 of 7 |
|
CME Program Director: E. David Crawford, MD
|
|
Topics covered include:
- Introduction
- Prostatectomy: Perineal or Retropubic
- Robotically Assisted Prostatectomy
- Primary and Salvage Cryosurgery
- Radiotherapy
Learning Objectives
Upon completion of this activity, participants should be able to:
Describe the rationale for use of the laparoscopic radical prostatectomy. Discuss the evidence for a dose response with external beam radiotherapy (EBRT). Identify the factors that define candidates for aggressive therapy vs watchful waiting. Examine the rationale for improved outcomes with third-generation cryosurgical devices. Review the evidence for neoadjuvant hormonal therapy and EBRT.
|
Hormonal Treatment of Prostate Cancer |
Module 3 of 7 |
|
CME Program Director: E. David Crawford, MD
|
|
Topics covered include:
- Introduction
- Use of LHRH Agonists in Combination With Radiation Therapy
- Combined Androgen Blockade with Antiandrogens and LHRH Agonists
- Optimal Timing of Hormone Therapy
- Conclusions
Learning Objectives
Upon completion of this activity, participants should be able to:
Discuss the optimal timing of hormone therapy. Describe various modes of androgen ablation therapy. Review strategies for extending survival with androgen ablation therapy.
|
Hormone-Refractory Prostate Cancer |
Module 4 of 7 |
|
CME Program Director: E. David Crawford, MD
 
- Christopher W. Ryan, MD
- Nicholas J. Vogelzang, MD
|
|
|
Topics covered include:
- Introduction
- Docetaxel Combinations for the Treatment of HRPC
- Epothilones for the Treatment of HRPC
- Platinum-Based Drugs for the Treatment of HRPC
- Vitamin D-Based Therapy
Learning Objectives
Upon completion of this activity, participants should be able to:
Review the use of novel targeted agents for HRPC Describe the use of current and novel chemotherapy regimens for HRPC Discuss the use of immunotherapies for HRPC
|
Monitoring Response, Prediction Methodology, Staging, and Imaging in Prostate Cancer |
Module 5 of 7 |
|
CME Program Director: E. David Crawford, MD
 
- James A. Eastham, MD
- Anne Rennea Simoneau, MD
|
|
|
Topics covered include:
- Introduction
- PSA for Monitoring Treatment Response
- Prediction Methodology
- Staging Systems for Prostate Cancer
- Stratification with Nomograms
Learning Objectives
Upon completion of this activity, participants should be able to:
Recount staging and imaging techniques and their use in stratifying patients with prostate cancer Describe the need for better tumor markers for monitoring late-stage disease Review nomograms and the concept of the predictability of indolent disease Discuss the utility of PSA screening in assessing present and future risk of prostate cancer
|
Treatment- and Disease-Related Complications in Prostate Cancer |
Module 6 of 7 |
|
CME Program Director: E. David Crawford, MD
- Paul H. Lange, MD, FACS
- Nicholas J. Vogelzang, MD
|
|
|
Topics covered include:
- Introduction
- Bone-Related Complications
- Erectile Dysfunction
- Urinary and Bowel Complications
- Other Health-Related Quality-of-Life Issues
Learning Objectives
Upon completion of this activity, participants should be able to:
Review health-related quality of life issue in prostate cancer patients. Describe the prevalence and prevention of genitourinary complications that occur with various prostate cancer treatment modalities. Discuss bone-related complications related to prostate cancer and its treatment.
|
Prevention and Complementary/Alternative Medicines in Prostate Cancer |
Module 7 of 7 |
|
CME Program Director: E. David Crawford, MD
|
|
Topics covered include:
- Introduction
- Complementary and Alternative Medicine
- Supplements Used by Men With Prostate Cancer
- Efficacy of CAM for Prostate Health
- Definition and Scope of Chemoprevention
Learning Objectives
Upon completion of this activity, participants should be able to:
Discuss new data regarding complementary and alternative medicines. Describe studies evaluating the use of chemopreventive agents in prostate cancer. Identify supplements used for prostate health.
|
Interactive Case Challenges
Locally Advanced Prostate Cancer in an Otherwise Healthy Elderly Patient
|
CME Program Director: E. David Crawford, MD
|
|
Learning Objectives
Upon completion of this activity, participants should be able to:
Describe the appropriate diagnostic workup for an elderly patient with increasing lower urinary tract symptoms. Review current treatment options for a patient with apparently localized high-risk prostate cancer who does not wish to undergo surgery. Discuss appropriate management strategies for a patient with a small rise in PSA after radiation therapy for apparently localized high-risk prostate cancer.
|
A Younger Patient at Risk for Prostate Cancer
|
CME Program Director: E. David Crawford, MD
|
|
Test your ability to manage a younger patient who has a first-degree relative with prostate cancer.
Learning Objectives
Upon completion of this activity, participants should be able to:
Describe the various management options for patients diagnosed with early stage prostate cancer. Discuss factors affecting detection of prostate cancer, including number of core biopsies, optimal prostate cancer screening intervals, and the relationship between prostate-specific antigen levels and prostatitis. Review data regarding prostate risk factors, particularly in individuals with high-normal prostate-specific antigen levels.
|
Disclaimer: The materials published on the Clinical Care Options
Web site reflect the views of the reviewers or authors of the
CCO
material, not those of Clinical Care Options, LLC, the CME provider,
or the companies providing educational grants. The materials may
discuss uses and dosages for therapeutic products that have not been
approved by the United States Food and Drug Administration. A qualified
healthcare professional should be consulted before using any therapeutic
product discussed. Readers should verify all information and data before
treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grants provided by:
Educational grants support only the CME-certified components of this program.
|